Chemomab Therapeutics Ltd. (NASDAQ:CMMB) Short Interest Update

Chemomab Therapeutics Ltd. (NASDAQ:CMMB) was the recipient of a significant decline in short interest during the month of February. As of February 15th, there was short interest totalling 29,300 shares, a decline of 60.9% from the January 31st total of 74,900 shares. Based on an average daily volume of 332,300 shares, the short-interest ratio is currently 0.1 days. Currently, 0.2% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the stock. Oppenheimer reaffirmed an “outperform” rating and issued a $11.00 target price (down previously from $13.00) on shares of Chemomab Therapeutics in a research report on Friday, November 15th. Maxim Group lifted their price objective on shares of Chemomab Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Thursday, February 20th.

Chemomab Therapeutics Stock Up 3.4 %

CMMB traded up $0.06 during trading hours on Friday, reaching $1.68. 9,714 shares of the company’s stock traded hands, compared to its average volume of 489,108. The firm has a market capitalization of $24.05 million, a PE ratio of -1.68 and a beta of 0.66. The firm has a 50-day moving average price of $1.97 and a 200 day moving average price of $1.73. Chemomab Therapeutics has a 52-week low of $0.58 and a 52-week high of $2.55.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Sphera Funds Management LTD. acquired a new stake in Chemomab Therapeutics during the 3rd quarter worth about $1,907,000. XTX Topco Ltd lifted its holdings in shares of Chemomab Therapeutics by 63.8% during the fourth quarter. XTX Topco Ltd now owns 24,929 shares of the company’s stock worth $45,000 after purchasing an additional 9,706 shares during the period. Finally, Virtu Financial LLC purchased a new stake in Chemomab Therapeutics in the fourth quarter valued at approximately $26,000. Institutional investors own 46.05% of the company’s stock.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).